Emulating Trials and Quantifying Bias: The Convergence of Health Technology Assessment Agency Real-World Evidence Guidance

被引：3

作者：

Chen, Simon ^{[1
]}

Tikhonovsky, Natalie ^{[1
]}

Dhanji, Nishit ^{[1
]}

Ramagopalan, Sreeram ^{[1
,2
]}

机构：

[1] Lane Clark & Peacock LLP, Hlth Analyt, London, England

[2] Kings Coll London, Ctr Pharmaceut Med Res, London, England

来源：

VALUE IN HEALTH | 2024年 / 27卷 / 02期

关键词：

D O I：

10.1016/j.jval.2023.11.010

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

引用

页码：265 / 267

页数：3

共 17 条

[1]

[Anonymous], Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer: technology appraisal guidance

[2]

[Anonymous], NICE real-world evidence framework

[3]

[Anonymous], Real-world studies for the assessment of medicinal products and medical devices

[4]

[Anonymous], Guidance for reporting real-world evidence

[5]

[Anonymous], Amivantamab for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy

[6]

[Anonymous], Mobocertinib for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy

[7] Feasibility of Using Real-World Data to Replicate Clinical Trial Evidence [J].

Bartlett, Victoria L. ;

Dhruva, Sanket S. ;

Shah, Nilay D. ;

Ryan, Patrick ;

Ross, Joseph S. .

JAMA NETWORK OPEN, 2019, 2 (10)

[8] The (Harsh) Reality of Real-World Data External Comparators for Health Technology Assessment [J].

Cox, Oliver ;

Sammon, Cormac ;

Simpson, Alex ;

Wasiak, Radek ;

Ramagopalan, Sreeram ;

Thorlund, Kristian .

VALUE IN HEALTH, 2022, 25 (07) :1253-1256

[9] Avoidable flaws in observational analyses: an application to statins and cancer [J].

Dickerman, Barbra A. ;

Garcia-Albeniz, Xabier ;

Logan, Roger W. ;

Denaxas, Spiros ;

Hernan, Miguel A. .

NATURE MEDICINE, 2019, 25 (10) :1601-+

[10]

Heyard R, medRxiv

← 1 2 →